Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Ovarian01: trastuzumab deruxtecan + bevacizumab vs bevacizumab maintenance in HER2-expressing ovarian cancer
CTR20251716Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2025; status: active.
02
Drugs
trastuzumab deruxtecanbevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20251716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251716.